» Articles » PMID: 12796776

BTLA is a Lymphocyte Inhibitory Receptor with Similarities to CTLA-4 and PD-1

Overview
Journal Nat Immunol
Date 2003 Jun 11
PMID 12796776
Citations 369
Authors
Affiliations
Soon will be listed here.
Abstract

During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).

Citing Articles

Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice.

Gherardi L, Aubergeon L, Sayah M, Fauny J, Dumortier H, Monneaux F Immunotargets Ther. 2025; 14():7-23.

PMID: 39845702 PMC: 11750947. DOI: 10.2147/ITT.S490573.


Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC).

Abah M, Ogenyi D, Zhilenkova A, Essogmo F, Ngaha Tchawe Y, Uchendu I Int J Mol Sci. 2025; 26(1.

PMID: 39796121 PMC: 11720203. DOI: 10.3390/ijms26010265.


Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients.

Aubergeon L, Felten R, Gottenberg J, Dumortier H, Monneaux F Cells. 2025; 13(24.

PMID: 39768154 PMC: 11674271. DOI: 10.3390/cells13242063.


Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer.

Liu X, Xi X, Xu S, Chu H, Hu P, Li D Front Immunol. 2024; 15:1507501.

PMID: 39726592 PMC: 11669709. DOI: 10.3389/fimmu.2024.1507501.


Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.

Anvari S, Nikbakht M, Vaezi M, Amini-Kafiabad S, Ahmadvand M Cancer Cell Int. 2024; 24(1):410.

PMID: 39702293 PMC: 11660508. DOI: 10.1186/s12935-024-03596-8.